Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 18/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.43 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.43 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.43 |
| ▸ | PLA2G2E | Q9NZK7 | 2/20 | 0.43 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.42 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.42 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.42 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.42 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.42 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.42 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770049 | 0.87 | PLA2G2A (0.42) | PLA2G2AFABP4FABP3 | |
| SCHEMBL5769684 | 0.85 | PLA2G2A (0.64) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL5767057 | 0.84 | FABP4 (0.46) | PLA2G2AFABP4FABP3 | |
| SCHEMBL5766359 | 0.83 | PLA2G2A (0.64) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL5768372 | 0.81 | PLA2G2A (0.46) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL5770181 | 0.81 | FABP4 (0.48) | PLA2G2AFABP4FABP3 | |
| SCHEMBL6393255 | 0.80 | PLA2G2A (0.47) | PLA2G2AFABP4FABP3 | |
| SCHEMBL5771305 | 0.78 | PLA2G2A (0.67) | PLA2G2AFABP4PLA2G1BPLA2G10PLA2G5 | |
| SCHEMBL6404040 | 0.78 | PLA2G2A (0.47) | PLA2G2AFABP4FABP3 | |
| SCHEMBL817831 | 0.78 | PLA2G2A (0.63) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349836-B1 | TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-06-14 | — | — | EP | disclosed |
| US-6992100-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040092543-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-05-13 | — | — | US | disclosed |
| EP-1349836-A2 | TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002050029-A2 | TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092543-A1 | Novel spla2 inhibitors | PLA2G12A, PLAAT2, SPINT2 | PLA2G2A 23/4885FABP4 261/4885PLA2G1B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.